InvestorsHub Logo
Followers 32
Posts 2803
Boards Moderated 3
Alias Born 10/24/2015

Re: None

Saturday, 04/23/2022 6:56:20 PM

Saturday, April 23, 2022 6:56:20 PM

Post# of 932
NeoPhore is developing first-in-class small molecule inhibitors to specifically block the MMR pathway in solid tumours. The company's scientific co-founders and SAB members Drs. Alberto Bardelli and Luis Diaz on new research showing that pharmacological inhibition of DNA mismatch repair can conceptually enhance patient responses to immunotherapy https://www.science.org/content/article/surprising-strategy-would-fight-mutant-cancer-cells-making-more-mutations